Denali Therapeutics Inc. DNLI announced that the FDA has granted Breakthrough Therapy Designation to its pipeline candidate, ...
Denali Therapeutics Inc. (NASDAQ: DNLI), today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tividenofusp alfa (DNL310) for the treatment ...
Denali Therapeutics Inc.'s stock remains stable despite trial setback in ALS. BLA filing for MPS II treatment on track. Click ...
About DNL310 and Hunter Syndrome (MPS II) Hunter syndrome (MPS II) is a rare neurodegenerative lysosomal storage disease caused by mutations in the gene that encodes for the enzyme iduronate-2 ...
DNL310 is an investigational enzyme replacement therapy designed to cross the BBB and address the behavioral, cognitive, and physical manifestations of MPS II. The interim data from the Phase 1/2 ...
The global robotic catheterization systems market opportunity are estimated to be worth USD 54.4 million in 2025 and anticipated to reach a value of USD 190.2 million by 2035. Sales are projected to ...
A first-to-market BBB-crossing biologic In March 2021, the first therapy using this technology, pabinafusp alfa, was approved in Japan for the treatment of mucopolysaccharidosis II (MPS II or ...
Politicians from both Houses of Parliament have gathered to mark the death of Queen Elizabeth II and share their memories ... special tributes in Parliament. MPs and ex-PMs paid their respects ...